PAT SM6

Drug Profile

PAT SM6

Alternative Names: PAT-SM6; SM-6

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator OncoMab GmbH
  • Developer Patrys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; LDL lipoprotein modulators; Molecular chaperone GRP78 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Malignant melanoma

Most Recent Events

  • 22 Sep 2015 PAT SM6 is still in phase-I/II development for Multiple myeloma in Germany
  • 18 Feb 2015 Patrys has patent protection for PAT SM6 in Europe
  • 29 Apr 2014 PAT SM6 is available for licensing as of 29 Apr 2014. http://www.patrys.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top